Krol Ewa, Agueel Rubina, Banue Sultana, Smogorzewski Miroslaw, Kumar Dinesh, Massry Shaul G
Division of Nephrology, University of Southern California School, Keck School of Medicine, Los Angeles, California, USA.
Kidney Int. 2003 Dec;64(6):2188-95. doi: 10.1046/j.1523-1755.2003.00311.x.
Patients with diabetes mellitus display an elevation in the basal levels of [Ca2+]i of polymorphonuclear leukocytes (PMNLs) and impaired phagocytosis. These derangements are due to the hyperglycemia of diabetes. Calcium channel blockers reverse these abnormalities both in in vitro studies and in diabetic rats. These observations suggest that calcium channel blockers may be useful in the treatment of patients with uncontrolled diabetes. The present study examined this issue.
A total of 32 normal subjects and 36 patients with uncontrolled noninsulin-dependent diabetes mellitus (NIDDM) were studied with and without treatment with amlodipine both in a cross-sectional and longitudinal design approach.
In addition to the elevation in basal levels of [Ca2+]i and the impaired phagocytosis, there was also down-regulation of the mRNA of Fc gamma RIII receptors in the PMNLs of the diabetic patients. Treatment of the patients with a small dose of amlodipine (5 mg/day) corrected these abnormalities despite persistent hypoglycemia. This beneficial effect of nifedipine was noted as long as the therapy with the drug was maintained.
The results show that the elevation in [Ca2+]i of the PMNLs is associated with down-regulation of the mRNA of their Fc gamma RIII receptors, which is at least, in part, responsible for the impaired phagocytosis. These derangements in the metabolism and function of the PMNLs are most likely responsible for the increased susceptibility of the diabetic patients to infection. Calcium channel blockers may be a beneficial adjunct therapy in patients with uncontrolled diabetes.
糖尿病患者的多形核白细胞(PMNLs)胞内钙离子([Ca2+]i)基础水平升高且吞噬功能受损。这些紊乱是由糖尿病的高血糖症所致。钙通道阻滞剂在体外研究和糖尿病大鼠中均可逆转这些异常。这些观察结果提示钙通道阻滞剂可能对治疗血糖控制不佳的糖尿病患者有用。本研究对这一问题进行了探讨。
采用横断面和纵向设计方法,对32名正常受试者和36名血糖控制不佳的非胰岛素依赖型糖尿病(NIDDM)患者在服用和未服用氨氯地平的情况下进行了研究。
除了[Ca2+]i基础水平升高和吞噬功能受损外,糖尿病患者PMNLs中的FcγRIII受体mRNA也下调。小剂量氨氯地平(5毫克/天)治疗可纠正这些异常,尽管血糖仍持续偏低。只要维持该药物治疗,硝苯地平的这种有益作用就会持续存在。
结果表明,PMNLs的[Ca2+]i升高与其FcγRIII受体mRNA下调有关,这至少部分导致了吞噬功能受损。PMNLs代谢和功能的这些紊乱很可能是糖尿病患者易感染的原因。钙通道阻滞剂可能是血糖控制不佳的糖尿病患者的一种有益辅助治疗方法。